[1]
T. Schlesinger, “Safety and Tolerability of Tirbanibulin 1% Treatment of Actinic Keratosis on Face and Scalp in Routine Clinical Practice Across the U.S. (PROAK Study)”, J of Skin, vol. 7, no. 6, p. s263, Nov. 2023.